First Mercantile Trust’s Tempest Therapeutics TPST Stock Holding History

First Mercantile Trust’s Portfolio TPST Stock Details TPST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-2	Closed	-$179K	–	1000
2015 Q2	$179K	Hold	2	–	–	0.02%	725
2015 Q1	$180K	Buy	+2	New	+$266K	0.01%	720

Other funds holding TPST

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Orbis Holdings Hamilton, Bermuda $12.8B AUM 8.29% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

First Mercantile Trust's TPST Position: Q3 2015 in Review

First Mercantile Trust sold out of Tempest Therapeutics (TPST) in Q3 2015, closing a stake of 2 shares — an estimated $179K sold.

First Mercantile Trust first reported a position in TPST in Q1 2015 and held it in 2 quarters. The position peaked at $180K in Q1 2015. 90 funds tracked by Wall St. Rank hold TPST as of Q3 2015.

First Mercantile Trust reported no remaining Tempest Therapeutics position as of Q3 2015 after selling out during the quarter.
First Mercantile Trust sold 2 Tempest Therapeutics shares in Q3 2015, an estimated $179K.
First Mercantile Trust first reported a position in Tempest Therapeutics in Q1 2015 and held it in 2 quarters.
First Mercantile Trust's Tempest Therapeutics position peaked at $180K in Q1 2015.
90 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q3 2015.

Based on First Mercantile Trust's 13F filing for Q3 2015, filed 13 Oct 2015.